ZCA
TGTX icon

Zeke Capital Advisors’s TG Therapeutics TGTX Stock Holding History

Zeke Capital Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,876
Closed -$295K – 330
2021
Q3 		$295K Buy
8,876
+1,750
+25% +$54.1K 0.02% 215
2021
Q2 		$276K Buy
+7,126
New +$280K 0.02% 248

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Zeke Capital Advisors's TGTX Position: Q4 2021 in Review

Zeke Capital Advisors sold out of TG Therapeutics (TGTX) in Q4 2021, closing a stake of 8,876 shares — an estimated $295K sold.

Zeke Capital Advisors first reported a position in TGTX in Q2 2021 and held it in 2 quarters. The position peaked at $295K in Q3 2021. 194 funds tracked by Wall St. Rank hold TGTX as of Q4 2021.

  • Zeke Capital Advisors reported no remaining TG Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Zeke Capital Advisors sold 8,876 TG Therapeutics shares in Q4 2021, an estimated $295K.
  • Zeke Capital Advisors first reported a position in TG Therapeutics in Q2 2021 and held it in 2 quarters.
  • Zeke Capital Advisors's TG Therapeutics position peaked at $295K in Q3 2021.
  • 194 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2021.

Based on Zeke Capital Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.